Company intelligence / Profile preview
CaaMTech
Issaquah, Washington, United Statescaam.tech ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
CaaMTech has synthesized and characterized hundreds of novel serotonergic compounds. Its lead program, CT-4201—a psilocin prodrug with improved pharmacokinetics—has received positive regulatory feedback for its clinical trial design targeting major depressive disorder. The company spun out Transneural Therapeutics in April 2025 to focus on non-hallucinogenic neuroplastogens for neuropsychiatric and neurodegenerative diseases.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Research collaborations with several research centers including Leibniz Institutes in Germany and UMass DartmouthNo major pharma partnerships disclosed as of June 2025.
Beyond the preview
Go deeper on CaaMTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CaaMTech.